All In Biotech

Drug Trial Radar · NCT00233532

Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,000

Actual

Start

Mar 2004

Primary completion

Jun 2005

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Oct 6, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Conditions

  • Hypertension

Interventions

  • TrandolaprilDrug

    0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness of escalating dose regimen of trandolapril in controlling blood pressureTime frame: 14 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.